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Introduction: Maternal cardiac dysfunction as well as abnormal uterine artery (UtA) 
Doppler are associated with hypertensive disorders of pregnancy (HDP), but their 
relationship is unclear. We investigated the correlation between maternal cardiac 
function, UtA hemodynamics and natriuretic peptides; and explored differences 
between women who subsequently develop HDP and those who did not. 
Material and methods: This was a prospective cross-sectional cohort study of 347 
pregnant women at 22-24 weeks. Maternal cardiac function and systemic 
hemodynamics was investigated at baseline and after 90 seconds of passive leg 
raising (PLR) using impedance cardiography. Preload reserve was defined as 
percent change (Δ%) in stroke volume (SV) and cardiac output (CO) from baseline to 
PLR. UtA hemodynamics was studied using Doppler ultrasonography. UtA blood 
flow, resistance and pulsatility index (PI) were calculated. Fasting venous blood 
samples were analyzed for natriuretic peptides (proANP, Nt-proBNP and CNP). The 
course and outcome of pregnancy was recorded. 
Results: At baseline, ProANP correlated significantly with CO (r= -0.122; p=0.023) 
and left cardiac work index (r= -0.112; p=0.037), whereas Nt-ProBNP correlated 
significantly with acceleration index (r=0.127; p=0.018) and velocity index  (r= -0.111; 
p=0.039. CNP correlated significantly with UtA blood flow (r=0.118; p=0.028) and 
resistance (r= -0.112; p=0.037) but not with UtA PI (r=0.034; p=0.523). None of the 
natriuretic peptides correlated with preload reserve. 
At 22-24 weeks, women who subsequently developed HDP had lower UtA blood flow 
(552 vs. 692 ml/min; p=0.028), higher UtA resistance (0.28 vs. 0.17mmHg/mL/min; 
p=0.004) and higher mean UtA PI (1.12 vs. 0.84; p<0.001) compared to those who 
did not, but had similar natriuretic peptide levels.  Women developing HDP had 
significantly higher increase in SV and CO and more reduction in systemic vascular 
resistance following PLR compared with the reference group.  Left cardiac work 
index, acceleration index, and velocity index  decreased following PLR in the 
reference group, whereas they increased in women who later developed HDP. 
Conclusions: ProANP correlated with CO and cardiac work, Nt-proBNP with indices 




natriuretic peptides measured at 22-24 weeks gestation reflected cardiac preload 
reserve or predicted development of HDP.  
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Key message: In pregnant women, natriuretic peptides measured at 22-24 weeks 
correlated with some parameters of baseline cardiovascular function, but did not 






Maternal cardiovascular remodeling is a physiological process required to adjust to 
the needs of the growing uterus, fetus and placenta. During pregnancy there is a 
substantial increase in circulating blood volume and cardiac output (CO), and a 
decrease in systemic vascular resistance (SVR). 1,2  
Passive leg raising (PLR), a maneuver of lifting the legs from the horizontal plane to 
45° using a pivotable bed, provides a rapid reversible auto-fluid challenge by 
increasing venous return to the heart.3 The homodynamic response to PLR can be 
used to assess preload reserve and functional hemodynamics.4,5 By using this 
method, we have previously shown that pregnant women have a limited preload 
reserve.6,7 
Atrial natriuretic peptide (ANP), brain natriuretic peptide(BNP) and C-type natriuretic 
peptide (CNP)  are the most important members of the natriuretic peptide family that 
are involved in maintaining volume homeostasis and endothelial function. ANP and 
BNP are of myocardial origin,8 and known to be produced in response to myocardial 
wall stress or pressure overload.9  Pro-ANP and pro-BNP are the principal storage 
form of of these peptide hormones that are cleaved into the active hormones ANP 
and BNP and an inactive fragment, N-terminal (Nt)-proANP and Nt-proBNP, 
respectively. CNP is a paracine hormone produced by the endothelium in response 
to vascular stress. 
In uncomplicated human pregnancies, ANP and BNP levels are similar or slightly 
higher compared with non-pregnant state, but remain stable throughout gestation.10-
12 Maternal plasma CNP is reduced in healthy pregnant women compared to non-
pregnant women, and levels tend to fall with advancing gestation.13 However, 
increased levels are found in pregnant women who later develop complications such 
as preeclampsia and/or fetal growth restriction.14 Levels of all these natriuretic 
peptides are known to be increased in preeclamptic pregnancies.14-16 
As the primary basis of their production during pregnancy is similar to that in non-
pregnant women, ANP and BNP could be adopted as biomarkers of early cardiac 
dysfunction or volume overload during pregnancy. Similarly, CNP could be used as a 




Both maternal systemic hemodynamic measurements and natriuretic peptide levels 
have been used to assess cardiac function in pregnancy.  However, the association 
between maternal cardiovascular hemodynamics and natriuretic peptides has not 
been elucidated. Furthermore, both abnormal uterine artery (UtA) Doppler blood flow 
velocity waveforms17 as well as vascular endothelial dysfunction18 in the first or 
second trimester of pregnancy are known to be associated with later development of 
preeclampsia. However, whether UtA hemodynamics correlates with maternal CNP 
levels is not known. Thus, our primary objective was to investigate the association 
between maternal cardiac function, preload reserve, UtA hemodynamics and 
natriuretic peptides at 22-24 weeks of gestation.  
Preeclampsia is known to be associated with cardiac dysfunction and remodeling.19 
Some researchers have found elevated natriuretic peptide levels in preeclampsia, 
15,16,20 and others have reported that asymptomatic cardiac dysfunction may be 
detected at mid-gestation in women who subsequently develop preeclampsia.21 
Therefore, our secondary objective was to explore differences in maternal functional 
hemodynamics and natriuretic peptide levels between women who subsequently 
develop hypertensive disorders of pregnancy (HDP) and those who do not. 
 
Material and methods 
This study was conducted from January 2009 to November 2013. The primary 
objective of the study was assessed in a cross-sectional design, while the secondary 
objective was assessed in a prospective cohort design. 
Pregnant women were informed about the study when they were attending the 
routine ultrasound screening at 17-20 weeks of gestation. Those women who agreed 
to participate and signed the informed consent were recruited consecutively and an 
appointment was made at 22-24 weeks of gestation for the evalaution of their 
cardiovascular function. These women were subsequently followed until delivery.  
Exclusion criteria were: age <18 years, chronic hypertension, multiple pregnancy and 
presence of any major fetal structural or chromosomal abnormalities.  
The participanting women were examined in a fasting state, in a quiet room with 
stable temperature maintained at approximately 22°C. Height and weight were 




electronic scale (Soehnle, Leifheit AG, Nassau, Germany), respectively. The body 
mass index (BMI) was calculated as weight/height2, and the body surface area (BSA) 
was calculated using the Du Bois formula22 as: BSA (m2) = 0.007184 x Height 0.725 
x Weight 0.425. The information on the course and outcome of pregnancy was 
obtained from the electronic hospital records. Gestational hypertension was defined 
as new-onset nonproteinuric hypertension (blood pressure ≥ 140/90 mmHg). 
Preeclampsia was defined as new-onset hypertension with proteinuria (≥1+ on a 
routine urinalysis or ≥ 300 mg/24 hours) or organ failure. HDP included both 
gestational hypertension and preeclampsia.  
 
Cardiac function and preload reserve 
Maternal cardiac function and systemic hemodynamics was investigated using ICG 
(Philips Medical Systems, Androver, MA, USA) as described previously.6,7,23  ICG is a 
validated noninvasive technique24 that allows continuous recording and on screen 
display of measured parameters. A single investigator (ÅV) performed all ICG 
measurements.  
Woman’s age, present weight and height were input into the ICG machine, central 
venous pressure (CVP) was preset at 4 mmHg and pulmonary artery occlusion 
pressure (PAOP) was preset at 8 mmHg. The following variables were continuously 
displayed on the ICG screen: cardiac output (CO),cardiac index (CI), heart rate (HR), 
systolic blood pressure (SBP), diastolic blood pressure (DBP), stroke volume (SV), 
stroke index (SI), thoracic fluid content (TFC)，systemic vascular resistance (SVR)，
systemic vascular resistance index (SVRI), acceleration cardiac index (ACI), left 
ventricular cardiac work index (LCWI), pre-ejection period (PEP), left ventricular 
ejection time (LVET), and velocity index (VI). The mean arterial blood pressure 
(MAP)  was calculated as DBP + 1/3 (SBP-DBP), SVR as (MAP-CVP)/CO x 80,  and 
systolic time ratio (STR) as PEP/ LVET.  
Baseline measurements were performed after approximately 10 minutes of rest with 
the pregnant woman lying in a 45° semi-recumbent position on an electronically 
pivotable bed. After the parameters were stabilized, baseline values were recorded. 
Then, the PLR maneuver was performed to assess preload reserve. The woman´s 




lowered to a supine position electronically steering the pivotable bed without any 
movements performed by the woman herself. Another set of measurements was 
recorded 90 seconds after PLR. The woman was instructed to remain quiet during 
the whole procedure. The cardiovascular response to PLR was expressed as percent 
change (Δ%) of the hemodynamic variables from baseline to PLR, i.e. (measurement 
after PLR - measurement at baseline) / measurement at baseline x 100%. The 
preload reserve was defined as Δ % of SV and CO from baseline to PLR.  
 
Uterine artery hemodynamics 
UtA hemodynamics was assessed by Doppler ultrasonography using an Acuson 
Sequoia 512 ultrasound system (Mountain View, CA, USA). Two experienced 
operators (CW and KF) performed all ultrasound examinations following the ALARA 
(as low as reasonably achievable) principle25 using the method described 
previously.23,26-28 UtA was identified transabdominally using color Doppler and blood 
flow velocity waveforms were recorded from the left and right UtA using pulsed-wave 
Doppler keeping the insonation angle as low as possible (always <30 degrees). UtA 
blood flow velocities were measured online using the software of the ultrasound 
machine. The uterine artery pulsatility index (UtA PI) was calculated as follows: UtA 
PI = (peak systolic velocity - end-diastolic velocity)/ time-averaged maximum velocity. 
An average of 3 consecutive waveforms was used for analysis. 
UtA diameter was measured using power Doppler angiography as described 
previously.23,26,27 UtA blood flow volume (Quta) was calculated as: Quta = UtA time-
averaged intensity weighted mean velocity x cross-sectional area of the UtA. The 
cross-sectional area was calculated as: 3.14x (UtA diameter/2)2. Total Quta was 
calculated as the sum of the left and the right Quta.  
The UtA resistance (Ruta) was calculated as: Ruta = MAP/total Quta.27 The fraction 
of maternal CO distributed to the uterus was calculated as total Quta/CO as 
described previously.29  
 
Natriuretic peptides 
Maternal fasting blood samples were obtained for analysis of the natriuretic peptides. 




antecubital vein. Peripheral blood was collected in ethylenediaminetetraacetic acid 
(EDTA) and serum tubes. EDTA plasma and serum were separated by centrifugation 
at room temperature for 10 minutes at 1250 g, transferred to cryotube (Sigma Aldrich 
Gmbh, Munich, Germany) and then immediately frozen at -70°C until analysis of 
natriuretic peptides was performed.  
Enzyme-linked Immuno-sorbent assay (ELISA) kits were used for quantification of 
natriuretic peptides according to the manufacturer’s instructions. EDTA plasma 
samples were used for the analysis of pro-ANP and CNP, whilst BNP was quantified 
in serum samples. The intra-assay coefficient of variation (CV) for pro-ANP ELISA kit 
(EIA-4703, DRG, Instruments, GmbH, Germany) was 5%, and the inter-assay CV 
was 9% and sensitivity (0 pmol/L +3SD). 
Nt-proBNP was quantified using a direct ELISA kit (EIA-4827, DRG Instruments, 
GmbH, Germany) that had an intra-assay CV of 4%, the inter-assay CV of 7% and 
sensitivity (0 pmol/L + 3SD): 3 pmol/L, detection range 0 – 640 pmol/L.   
CNP was analyzed using a human C-type natriuretic peptide kit (CSB-E08909h, 
CUSABIO, Lab-Tech AS, Norway) that had an intra-assay CV of 8%, the inter-
assay CV of 10%, and detection range 62.5 - 4000 pg/ml. 
 
Statistical analyses 
Data were analyzed using IBM SPSS statistics (SPSS software, version 24.0.0, 
Chicago, IL, USA). Variables were presented as mean (±SD), median (range) or n 
(%) as appropriate. Statistical significance was set as a two-sided p-value of <0.05. 
Assumption of normality was checked for each variable using Shapiro-Wilk test. 
When the variables could be assumed to be normally distributed, independent 
sample t-test was used for comparison between reference group and HDP group, 
and paired-sample t-test was used for comparison between measurements obtained 
on the same women at baseline and 90s after PLR. When the variables were not 
normally distributed, nonparametric Wilcoxon test was used. Chi-square test was 
applied for the analysis of differences in proportions between groups. Nonparametric 
Spearman rank correlation test was used to assess correlation of natriuretic peptides, 
which were not normally distributed,  with variables describing maternal cardiac 




Ethical approval:  
The study protocol was approved by the Regional Committee for Medical and Health 
Research Ethics - North Norway (Ref.nr. 5.2005.1386. Date of approval: 
12.03.2010). 
Results 
Of a total of 350 pregnant women recruited to the study, three were excluded 
because of missing blood samples and 347 were included in the final statistical 
analysis. Thirty-three (9.5%) women developed HDP later in the pregnancy (17 
cases of gestational hypertension and 16 cases of preeclampsia), 80.7% had an 
uncomplicated vaginal delivery, 5.8% had an operative vaginal delivery and 13.5% 
were delivered by cesarean section. Twenty-one women delivered pre-term: 10 in the 
reference group (10/312, 3.2%) and 11 in the HDP group (11/33, 33.3%) (p<0.001). 
The differences in baseline characteristics between the reference group and the HDP 
group are presented in Table 1. There was no significant difference in maternal age 
(p =0.459), but the HDP group had significantly higher BMI (p=0.010) and MAP 
(p<0.001). The HDP group delivered earlier in gestation ( p=0.008), and had lower 
birthweight babies (p=0.002) with lower 5-minute Apgar score (p=0.001) and  lower 
placental weight (p=0.036). 
Maternal cardiac function and systemic  hemodynamic measurements obtained at 
baseline and 90 seconds after PLR are shown in Table 2. At baseline, ProANP 
correlated significantly with CO (r= -0.122; p=0.023) and LCWI (r= -0.112; p=0.037). 
Nt-proBNP correlated significantly with ACI (r=0.127; p=0.018)  and VI (r= -0.111; 
p=0.039). CNP correlated significantly with Quta (r=0.118; p=0.028) and Ruta (r= -
0.112; p=0.037) but not with UtA PI (r=0.034; p=0.523).  
During PLR, ProANP correlated significantly with Δ % DBP (r= -0.124; p=0.021), Δ % 
MAP (r= -0.142; p=0.008) ,  Nt-ProBNP correlated significantly with Δ % DBP (r= -
0.134; p=0.013). However, none of the natriutetic peptides correlated significantly 
with preload reserve.  
Women who subsequently developed HDP had significantly higher increase in SV 
and CO and more reduction in SVR following PLR compared with the reference 
group.  ACI, VI and  LCWI  decreased following PLR in the reference group, whereas 




Maternal UtA hemodynamics and natriuretic peptide levels in reference group and 
HDP group are presented in Table 3. At 22-24weeks, women who subsequently 
developed HDP had higher mean UtA PI (1.12 vs. 0.84; p<0.001), lower total Quta 
(552 vs. 692 ml/min; p=0.028) and higher Ruta (0.28 vs. 0.17mmHg/mL/min; 
p=0.004) compared to those who did not, but had similar natriuretic peptide levels.  
 
Discussion  
In this study we evaluated whether there is an association between maternal 
natriuretic peptides and cardiovascular function in pregnant women at 22-24 weeks 
of gestation and explored differences between women who had normal pregnancy 
outcome and those who subsequently developed HDP. We observed that none of the 
natriuretic peptides reflected maternal cardiac preload reserve or predicted 
development of HDP in the third trimester of pregnancy. ProANP correlated with CO, 
a major determinant of global oxygen delivery, but Nt-proBNP did not. However, both 
ProANP and Nt-proBNP correlated with cardiac work (LCWI). CNP correlated with 
UtA blood flow and resistance but not with maternal cardiac function. Women who 
developed HDP later in pregnancy had significantly higher increase in SV and CO 
and more reduction in SVR following PLR compared with the reference group.  The 
varibles describing cardiac contractilty and work (ACI, VI and  LCWI)  decreased in 
the reference group after PLR whereas they increased in women who later 
developed HDP.  
Cardiac function is affected by pregnancy due to an increase in preload and a 
decrease in afterload, and these changes are clearly evident by mid-gestation, but 
the preload reserve, i.e. the ability of the heart to increase its output in response to a 
rapid transient increase in venous return, is limited in the second half of pregnancy,6,7 
most likely due to cardiovascular remodeling as a result of increased volume load. 
When the heart has adapted to chronic volume load, as in normal pregnancy, there is 
still a perfect match of afterload with inotropic state, but with essentially maximum 
use of preload. Therefore, with limited preload reserve a mismatch between afterload 
and inotropic state can happen. As a result, with increasing afterload, the LV may not 
be able to maintain its SV when preload is fully utilized (i.e. the limit of the preload 
reserve is reached).30,31 Hameed et al.11 have shown that BNP levels are 




and they do not significantly fluctuate. NT-proBNP appears to increase until mid-
pregnancy, suggesting a correlation with volume expansion,32 and probably reflecting 
the physiological increase in CO during pregnancy. However, in our study, the Nt-
proBNP levels measured at 22-24 weeks did not correlate with CO, but ProANP, 
which is known to increase with myocardial stress, had a negative correlation with 
CO and LCWI suggesting that volume overload may negatively effect cardiac 
performance in pregnancy.  
The circulatory volume is usually reduced in women with HDP, and untreated 
patients  with preeclampsia who have increased SVR respond to plasma volume 
expansion by increasing their CO.33 In our cohort, women who developed HDP later 
in gestation, increased their SV and CO, and improved their ICG-derived indices of 
cardiac contractility during PLR at 22-24 weeks, suggesting that these women might 
be slightly volume depleted already in mid-gestation due to an inadequate increase in 
plasma volume. Therefore, their heart responds to small increase in preload caused 
by transient increase in venous return as a result of PLR.  
Hemodynamics is generally expressed  as flow-pressure relationship, although it is 
the flow component that continuously adapts to the changing demands of the tissues 
and organs for oxygen delivery. At baseline, proANP correlated negatively with CO 
and LCWI, NT-ProBNP correlated positively with ACI and VI, whereas CNP didn’t 
correlate with any of the parameters of cardiac function measured by ICG. None of 
the natriuretic peptides correlated with change in SV or CO caused by PLR, 
suggesting that they do not reflect preload reserve in pregnant women during 22-24 
weeks of gestation. Although ProANP and NT-ProBNP correlated negatively with Δ 
% BPD and proANP correlated  negatively with Δ % MAP, no significant correlation 
was found between these natriuretic peptides and Δ % SVR suggesting that the 
reduction in SVR following volume expansion observed in preeclamptic women33 may 
be a result of improved cardiac performance rather than afterload reduction.    
It is known that second trimester abnormal UtA Doppler velocity waveform is 
associated with increased risk of developing HDP later in pregnancy.17 As expected, 
in our study, women who developed HDP in the third trimester had higher UtA PI, 
lower Quta and higher Ruta at 22-24 weeks. Interestingly, ANP and  BNP did not 
correlate with UtA hemodynamics but CNP correlated positively with UtA blood flow 




reflect uterine vascular  endothelial dysfunction, which may precede the development 
of HDP. In our study, CNP did not significantly correlate with UtA PI. This is not 
surprising as UtA PI, although considered a surrogate measure of utero-placental 
impedance, does not always reflect the Ruta34 or maternal endothelial function.23 
Untreated women with HDP, especially those with placental insufficiency, have high 
SVR and low cardiac index,35,36 and plasma levels of ANP and BNP are reported to 
be higher in preeclamptic women compared to normotensive pregnant women.15,16,20 
Furthermore, ANP and BNP are shown to be linearly related to the left ventricular 
structural and functional changes observed in women with preeclampsia.37 However, 
whether these natriuretic peptides are more sensitive markers of cardiac dysfunction 
in pregnancy compared to other parameters of cardiovascular function, is not known. 
Using tissue Doppler and strain rate analysis, asymptomatic cardiac diastolic 
dysfunction has been reported to be present at 20-23 weeks of gestation in women 
who subsequently develop preterm preeclampsia requiring delivery before 37 
weeks.21 In our study, natriuretic peptide levels at 22-24 weeks were similar among 
women who subsequently developed HDP and those who did not. However, due to a 
small number of women that developed preeclampsia, subgroup analysis stratifying 
different types of HDP was not possible, and the value of mid-gestation maternal 
ANP and BNP in predicting HDP remains unclear. 
Significantly elevated tissue Doppler E/E´ ratio has been reported in preeclamptic 
compared to the normotensive pregnant women. This increase has been attributed to 
a rise in the tissue Doppler early filling wave (E´) and has been suggested to reflect 
rising cardiac filling pressures in preeclampsia.38 However, it has been shown that 
preeclamptic women are preload responsive, i.e. they increase their CO in response 
to volume load.33,39 Although in clinical practice pulmonary artery occlusion pressure 
is considered to reflect preload (pressure is easier to assess than the flow and 
volume), preload is related to filling blood volume rather than the filling pressure; and 
left atrial and ventricular pressures are a function of blood inflow and chamber 
compliance. Pregnant women, who are generally young, have a complaint ventricular 
wall and can be volume overloaded despite normal filling pressures. 
A strength of our study is its relatively large sample size. To our knowlege it is the 
largest study so far evaluating maternal cardiac function, using ICG and natriuretic 




hemodynamics and correlated it with CNP, a known marker of vascular endothelial 
function. There are no previoius studies that have simultaneously evaluated CNP and 
UtA  blood flow during pregnancy. However, the number of participants included was 
not sufficient to draw definitive conclusions regarding predictive value of mid-gestaion 
maternal functional hemodynamics and natriuretic peptides in predicting subsequent 
development of HDP. Similarly due to small number of cases with HDP, subanalysis 
by stratification into different types of HDP (such as early and late onset) was not 
possible. 
Although the values of natriuretic peptides are reported to be stable during pregnacy, 
the cross-sectional design of our study does not allow us to draw conclusions 
regarding temporal changes in natriuretic peptide levels and their association with 
maternal functional hemodynamics throughout the pregnancy. Ethnic differences in 
BNP have been reported in term pregnancies,12 and as our study population 
consisted mainly of homogenous North European women, the findings may not be 
generalizable to other ethnic populations.  
Conclusions  
ProANP correlated with CO and cardiac work, Nt-proBNP with indices of cardiac 
contractility, and CNP with UtA blood flow and resistance. None of these natriuretic 
peptides measured at 22-24 weeks of gestation reflected cardiac preload reserve or 
predicted development of HDP. There appears to be no additional clinical value of 
measuring natriuretic peptides to screen pregnant women in the second trimester for 
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